Recent secondary market transactions have driven Neuralink's implied valuation to the $42–60 billion range as of October 2026, representing a sharp increase from the roughly $9.7 billion post-money valuation in its June 2025 Series E round. This repricing reflects sustained investor appetite for the company's brain-computer interface progress, including expanded clinical trial enrollment beyond 21 participants, record cursor-control performance from neural data models, and plans for high-volume implant production and automated surgery in 2026. Additional tailwinds include the hiring of a former FDA neurological devices regulator and validation of Elon Musk's broader portfolio following SpaceX's large-scale IPO. With the December 31 resolution date approaching, upcoming trial readouts, manufacturing milestones, and any further secondary liquidity events will likely shape trader-implied odds around further valuation expansion.